Click chemistry and radioscience: Zeng and colleagues provide a brief history and overview of the growing importance of bioorthogonal click chemistry in the development of radiopharmaceuticals, focusing on advantages in modularity, reliability, selectivity, and efficiency.
18F-FCH in recurrent prostate cancer: Beheshti and colleagues assess the diagnostic accuracy of this agent in PET/CT detection of recurrent disease or distant metastases and correlate results with prostate-specific antigen levels and histories of androgen deprivation therapy.
PET/CT in head and neck cancer: Sharma and colleagues describe the role of 68Ga-labeled DOTANOC PET/CT for baseline evaluation of patients with head and neck paragangliomas and compare results with those from 131I-MIBG scintigraphy and CT/MR imaging.
Early PET for HCC hyperperfusion: Schierz and colleagues detail and pilot a simplified protocol for early dynamic 18F-FDG PET/CT evaluation of hepatocellular carcinoma liver nodule hypervascularization.
68Ga-DOTATATE dosimetry: Walker and colleagues report on measured human dosimetry of the 68Ga-labeled synthetic somatostatin analog 68Ga-DOTATATE, an investigational PET/CT imaging agent that binds with high affinity to somatostatin receptor subtype 2.
18F-FSPG dosimetry: Smolarz and colleagues provide dosimetry estimates for this new glutamic acid–derivative PET tracer for detection of malignant diseases and discuss its promise in non–small cell lung cancer.
BAY86-7548 metabolism and dosimetry: Roivainen and colleagues offer the first-in-human study investigating the safety, tolerability, metabolism, pharmacokinetics, biodistribution, and radiation dosimetry of this 68Ga-labeled bombesin antagonist for PET/CT imaging in prostate cancer.
Dynamic myocardial perfusion SPECT: Ben-Haim and colleagues assess the feasibility of dynamic tomographic SPECT imaging and quantification of a retention index to describe global and regional myocardial perfusion reserve using a dedicated solid-state cardiac camera.
11C-PiB vs. 18F-AZD4694: Rowe and colleagues compare the cortical and white matter binding of 18F-AZD4694, a new amyloid-β tracer, with that of 11C-Pittsburgh compound B in healthy elderly participants and individuals with varying levels of cognitive impairment.
Combined-tracer imaging in MCI: Albin and colleagues describe PET-based classification of neurodegenerative pathology in mild cognitive impairment with 11C-dihydotetrabenazine PET assessment of striatal dopamine terminal integrity and 11C-Pittsburgh compound B PET estimation of cerebral amyloid burden.
Metabolic networks and cognitive reserve: Morbelli and colleagues investigate the metabolic basis for resilience to neurodegeneration and for neural compensation in highly educated patients with prodromal Alzheimer disease.
PET proliferation imaging: Tehrani and Shields provide an educational overview of tumor proliferation with labeled pyrimidine analogs, with a focus on 18F-fluorothymidine and early assessment of treatment response.
Anti-EGFR RIT in breast cancer: Al-Ejeh and colleagues employ epidermal growth factor receptor as a target for radioimmunotherapy in a mouse model of triple-negative breast cancer.
Prostate tumor redox status: Keshari and collagues describe development of a hyperpolarized, oxidized form of vitamin C as an MR probe and assess its performance and that of 18F-FDG PET in a model of transgenic adenocarcinoma of the mouse prostate.
89Zr-RO5323441 PlGF PET: Oude Munnink and colleagues describe radiolabeling and preclinical validation of this humanized monoclonal antibody against placental growth factor, a member of the proangiogenic vascular endothelial growth factor family upregulated in many tumors.
PET and afatinib treatment: Janjigian and colleagues evaluate the ability of 89Zr-trastuzumab PET to identify HER2-positive gastric cancer and to monitor the pharmacodynamic effects of afatinib, an epidermal growth factor receptor/human epidermal growth factor receptor 2 tyrosine kinase inhibitor.
Bone metastasis characterization: Doré-Savard and colleagues report on longitudinal monitoring of bone tumor progression using small animal PET/MR image coregistration to improve noninvasive imaging–assisted diagnoses.
Disulfiram and copper cytotoxicity: Rae and colleagues determine through in vitro and in vivo studies the potential of disulfiram to enhance the antitumor efficacy of external-beam γ-irradiation and 131I-MIBG in neuroendocrine tumors.
Novel targeting therapeutic Affibody: Orlova and colleagues detail the design and evaluation of 177Lu-ABY-027, a new targeting Affibody–albumin-binding domain fusion protein with improved biodistribution properties for radionuclide therapy.
Awake small-animal neuroimaging: Baba and colleagues describe development of and initial studies with a SPECT imaging system that enables molecular brain imaging of untrained, conscious, unanesthetized, and unrestrained mice.
Apoptosis imaging of engrafted MSCs: Godier-Furnémont and colleagues use dual-tracer 99mTc-HYNIC annexin V and 201Tl SPECT/CT imaging to assess the cardioprotective effects of a conditioned mesenchymal stem cell patch in a rat model of acute myocardial infarction.
Reporter genes and MCAO models: Wu and colleagues explore the feasibility of and methods for imaging bone marrow stem cells with a novel reporter gene–probe system in experimental middle cerebral artery occlusion rat models.
Gene regulation at low-dose 211At: Langen and colleagues elucidate the effect of α-particle exposure from administration of 211At on transcriptional gene regulation in normal animal tissues in the kidney cortex and medulla, liver, lungs, and spleen.
18F-FDG and USPIO in atherosclerosis: Satomi and colleagues investigate intracellular 18F-FDG and ultrasmall superparamagnetic iron oxide particle accumulation in differently polarized macrophages.
- © 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.